A mitochondria-derived peptide that acts as an 'exercise mimetic' — improving metabolism and insulin sensitivity.
MOTS-c is a 16-amino acid peptide encoded within the mitochondrial genome — specifically in the 12S ribosomal RNA gene. It was discovered by Pinchas Cohen at USC in 2015 and represents a new class of biological regulator: mitochondria-derived peptides (MDPs). Unlike nuclear-encoded peptides, MOTS-c is produced by the mitochondria themselves.
MOTS-c functions as a metabolic regulator, acting to improve insulin sensitivity, increase glucose uptake in skeletal muscle, and enhance fat oxidation. Remarkably, it mimics many of the metabolic benefits of exercise — hence the term 'exercise mimetic.' Blood levels of MOTS-c naturally increase during physical exercise and decline with age.
The discovery that mitochondria encode functional peptides was itself a significant biological finding. MOTS-c can translocate from mitochondria to the nucleus, where it regulates gene expression in response to metabolic stress. This nuclear signaling role adds complexity to its biology and potential therapeutic applications.
Mouse studies demonstrate that MOTS-c administration improves exercise capacity, reverses diet-induced obesity and insulin resistance, and extends lifespan in some aging models. The metabolic improvements occur without apparent toxicity. Human blood levels of MOTS-c correlate with metabolic health and decline with age and obesity.
The first human administration study (Phase 1) published in 2022 showed safe pharmacokinetics in healthy volunteers. Human efficacy trials for metabolic disorders and aging are in early stages. MOTS-c is one of the most scientifically novel peptides in active research.
📚 Key Reference: PMID: 25738459 (MOTS-c discovery), PMID: 36008916 (human Phase 1)
Limited human data. Phase 1 study showed safety in healthy volunteers. Animal studies show no significant toxicity. As with all research peptides, quality of source material and long-term effects are unknown. Consult your provider.
NOT FDA-approved. Research use only. In early human clinical trials. Available through some specialized compounding pharmacies. One of the most scientifically novel peptides — but clinical evidence is early-stage.